Indiziert in
- Öffnen Sie das J-Tor
- Genamics JournalSeek
- CiteFactor
- RefSeek
- Hamdard-Universität
- EBSCO AZ
- NSD – Norwegisches Zentrum für Forschungsdaten
- OCLC – WorldCat
- Publons
- Genfer Stiftung für medizinische Ausbildung und Forschung
- Euro-Pub
- Google Scholar
Nützliche Links
Teile diese Seite
Zeitschriftenflyer
Open-Access-Zeitschriften
- Allgemeine Wissenschaft
- Biochemie
- Bioinformatik und Systembiologie
- Chemie
- Genetik und Molekularbiologie
- Immunologie und Mikrobiologie
- Klinische Wissenschaften
- Krankenpflege und Gesundheitsfürsorge
- Landwirtschaft und Aquakultur
- Lebensmittel & Ernährung
- Maschinenbau
- Materialwissenschaften
- Medizinische Wissenschaften
- Neurowissenschaften und Psychologie
- Pharmazeutische Wissenschaften
- Umweltwissenschaften
- Veterinärwissenschaften
- Wirtschaft & Management
Abstrakt
A Novel Versatile Antibody-Drug Conjugate for Cancer Therapy
Chuan-Lung Hsu
Abstract
Antibody drug forms (ADCs), a promising cutting edge counter acting agent drug, join tumor particularity with exceptionally powerful cytotoxic payload for improve remedial adequacy in disease treatment. Nonetheless, because of the assembling issues and delivering heterogeneous results of irregular formation of ADCs, here we report a profoundly effective glycogengineering innovation by utilizing a GnT-I (N-Acetyl glucosamine transferase I) and a GnT-II (N-Acetyl glucosamine transferase II) as proteins to form a tri-mannosyl center immunizer and produce an adaptable ADC. Our results show that a homogenous tri-mannosyl Herceptin-2(GlcNAc-triazole-DBCO-(PEG)4-DM1)- 2(GlcNAc-triazole-DBCO-PEG4-Vc-PAB-(PEG)2-Duocarmycin) is made with the change efficiency over 90% and half recovery rate.The outcomes demonstrate that the tri-mannosyl ADC has not just with exceptionally strong cytotoxicity (IC50<1.2 nM) than Kadcyla, yet additionally with better enemy of tumor development movement in BT-474 and N87 xenograft (TGI>90%)